Clinical Trial Update: Afatinib Genomic Landscape

View source ↗

Summary

A clinical trial update on afatinib exploring its genomic landscape in non-small cell lung cancer reports a terminated study (NCT02491775).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer | Status: TERMINATED